Disclosure of Directors' Appointments

RNS Number : 1223H

Ergomed plc

15 August 2016

 

PRESS RELEASE

FOR IMMEDIATE RELEASE

15 August 2016

Ergomed Plc

Disclosure of Directors' Appointments

Pursuant to AIM Rule 17 and Schedule 2 Annex III of the AIM Rules, Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company') provides the following updated disclosures relating to its directors.

Rolf Stahel (Chairman):

Current Directorships

Ergomed Plc  

Chesyl Pharma Limited

Midatech Pharma Plc

Connexios Life Sciences Pvt Limited

Previous Directorships (last five years)        

Midatech Limited

Newron Pharmaceuticals Spa           

Cosmo Pharmaceuticals Spa           

Eusa Pharma Inc

Miroslav Reljanovic (Chief Executive Officer):

Current Directorships

Ergomed Plc

Ergomed Clinical Research Limited

Primevigilance Limited

Sound Opinion Limited

Ergomed Istrazivanja d.o.o.

Ergomed GmbH

Ergomed LLC

Ergomed Clinical Research FZ LLC

Ergomed Clinical Research, Inc

Ergomed d.o.o.

Ksa Jv Ergomed

Ergomed Virtuoso Sarl

Lincetovo d.o.o.

Ljetnikovac Lantana d.o.o.

Haemostatix Limited

Stephen Stamp (Chief Financial Officer):

Current Directorships

Ergomed Plc

Storm Pharmaceuticals, Inc

Haemostatix Limited

Neil Clark (Executive Director):

Current Directorships

Ergomed Plc

Primevigilance Limited

Ergomed Clinical Research Limited

Sound Opinion Limited

Ergomed GmbH

Primevigilance Inc

Ksa Jv Ergomed

Ergomed Virtuoso Sarl

Andrew Mackie (Chief Business Officer):

Current Directorships

Ergomed Plc

Montagu Pharma Limited

Haemostatix Limited

Previous Directorships (last five years)

Am Pharma Consulting Limited

Peter George (Non-Executive Director):

Current Directorships

Ergomed Plc

Clinigen Clinical Trials Limited

Clinigen CTS Limited

Clinigen GAP Limited

Clinigen Group Plc

Clinigen Healthcare Limited

Clinigen Pharma Limited

Clinigen Sp Limited

Idis Ga Limited

Idis Group Limited

Idis Limited

Idis Ma Limited

Idis Pharma Limited

Idis Trustee (Uk) Limited

Idis Inc (US)

Keats Healthcare Limited

Xpg Limited

Wichtig International Limited

454 Daniel and Donna Lda

Clinigen CTS Inc (US)

Peter George was a director of UCT (UK) Limited from 26 July 1999 until its dissolution on 6 November 2004 following a voluntary creditors liquidation.

Christopher Collins (Non-Executive Director):

Current Directorships

Ergomed Plc

Rx Securities Limited

Eidos Pharma Limited

Previous Directorships (last five years)

Nomura Code Securities Limited

- ENDS -

Enquiries:

Ergomed Plc Miroslav Reljanovic (Chief  Executive Officer) Stephen Stamp (Chief Financial Officer)	Tel: [phone]
Numis Securities Limited Michael Meade / Freddie Barnfield (Nominated Adviser)           James Black (Joint Broker)	Tel: [phone]
Stifel Nicolaus Europe Limited Jonathan Senior (Joint Broker)	Tel: [phone]
FTI Consulting Simon Conway / Mo Noonan / Natalie Garland-Collins	Tel: [phone]

About Ergomed

Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries.

Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.

Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.

As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed recently acquired a pipeline of proprietary development products for haemostasis in surgical settings. For further information, visit: http://ergomedplc.com.

 

END

 

 

RDNGGUMARUPQGMC